Sector News

GSK sells French research center to Oncodesign

September 29, 2016
Life sciences

GlaxoSmithKline (GSK) has sold its François Hyafil Research Centre in Villebon-sur-Yvette (Essonne), France, to Oncodesign, the buyer said today.

In return, GSK agreed to pay Oncodesign €35 million ($39 million) to support the facility over 4 years. Oncodesign said it would use the money to integrate the site and its operations into its business and ensure the continued employment of the center’s 57 employees during the period.

The agreement is expected to be completed on or about December 1.

“It will allow Oncodesign to boost its drug discovery programs and experimentation businesses and to position itself as a leading player in the business of full drug discovery services, a new market for Oncodesign,” Philippe Genne, Ph.D., the company’s CEO and founder, said in a statement.

Dr. Genne added that the acquisition of the research center will expand Oncodesign’s presence in France’s Paris-Saclay regional innovation cluster—as well as accelerate the company’s partnership launched in January with Bristol-Myers Squibb (BMS), and partnerships with Ipsen and UCB. The pharma giants are among Oncodesign’s more than 600 clients.

“In addition, it will speed up our Nanocyclix-based drug discovery internal programs through increased capabilities and productivity in both oncology and nononcology areas,” Dr. Genne added.

The research center was established in 1987, and has been based at its current site since it opened in 2010. The center was designed to support drug discovery and incubate new science within GSK by providing scientific expertise and resources that included delivery of medicinal chemistry, biology, in vivo pharmacology, and drug metabolism/pharmacokinetics capabilities with experience in many therapeutic areas.

After GSK opted to consolidate its R&D operations around two major hubs—Stevenage, U.K., and the Upper Providence site in Collegeville, PA—the pharma giant said in September 2015 it would seek a buyer for the François Hyafil Research Centre.

GSK employs more than 3500 people in France, where it has three production sites, a clinical research center, and a head office in Marly-le-Roi. Oncodesign is a drug discovery firm and oncology pharmacology service provider that employs 108 people and is based in Dijon, France.

Source: GEN

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach